Humanigen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.humanigen.com
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT04351152
- Locations
- 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Dartmouth-Hitchcock, Lebanon, New Hampshire, United States
🇧🇷Hospital Guilherme Alvaro, Santos, São Paulo, Brazil
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02546284
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Mayo Clinic Cancer Center Clinical Research, Rochester, Minnesota, United States
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT01695343
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT01603277
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase 1
Suspended
- Conditions
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01211691
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00995449
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2009-07-31
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00691587
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00638365
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2024. All Rights Reserved by MedPath